[{"Assets_0_Q2_USD":587043000.0,"CommonStockSharesOutstanding_0_Q2_shares":122645334.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-91143000.0,"NetIncomeLoss_1_Q2_USD":-56762000.0,"NetIncomeLoss_2_Q2_USD":-164833000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":122549000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":122415000.0,"StockholdersEquity_0_Q2_USD":83529000.0,"EarningsPerShareBasic_1_Q2_USD":-0.46,"EarningsPerShareBasic_2_Q2_USD":-1.35,"Ticker":"SRNE","CIK":"850261","name":"SORRENTO THERAPEUTICS, INC.","OfficialName":"Sorrento Therapeutics Inc.  Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"636044097.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20190809"}]